InvestorsHub Logo
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Monday, 03/13/2017 5:57:43 PM

Monday, March 13, 2017 5:57:43 PM

Post# of 425
FDA approves NVS’ Kisqali (f/k/a LEE011) for first-line HR+/HER2- breast cancer:

https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment

The main competitor for Kisqali is PFE’s Ibrance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVS News